Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +45.25%
#2 Mubarak Mubarak +42.17%
#3 Pons Pons +38.98%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.88%
#5 Starpower Starpower +28.91%
#6 Bitway Bitway +25.89%
#7 SkyAI SkyAI +24.04%
#8 TENDIES TENDIES +22.47%
#9 StonkBroker StonkBroker +20.76%
#10 Decred Decred +20.59%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
ABVC BioPharma, Inc. ABVC BioPharma, Inc.

ABVC BioPharma, Inc.

ABVC
Classifica tra le azioni #28867
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on... ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Prezzo delle azioni
$0.9201
Capitalizzazione di mercato
$23.92M
Variazione (1 giorno)
6.23%
Variazione (1 anno)
-67.72%
Paese
US
Scambia ABVC BioPharma, Inc. (ABVC)

Categoria

Healthcare
Rapporto P/S per ABVC BioPharma, Inc. (ABVC)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di ABVC BioPharma, Inc., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per ABVC BioPharma, Inc. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH